Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

LiquidThetaLEAPS Oct. 18 at 6:40 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $JNJ Current Share Price: $192.12 Contracts: $JNJ December 18, 2026 $195 Calls Scale in: $13.28- $16.23 Scale out: $20.65-$26.55 Can Easily Capture: 60% ROI Blended DTE: 427 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

dDxsm8 Oct. 18 at 5:43 AM

?? High-conviction cluster — risk-defined entries only! ???? ?? Portfolio: $EXPE $LOW $XOM $META $JNJ ?? Why this cluster: Clean technical bases with improving relative strength; catalysts may trigger a rapid move. EXPE shows relative strength; LOW is base-building; XOM is a stealth accumulator; META offers sector exposure; JNJ provides stability. ?? Execution: Tip: scale in with size discipline; add on volume-confirmed strength. ?? ???? #AlphaHunt #Tactical ???? ?? Source: https://stocktwits.com/JacquelinePope8149/message/632828907

0 · Reply

investblwiit Oct. 18 at 5:13 AM

?? Hot setup alert — potential multi-leg move incoming! ???? ?? Portfolio: $JNJ $COST $BAC $BKNG $REGN ?? Why this cluster: Accumulation noted, range tightening, and cross-sector flow suggests rotation into these names. JNJ shows relative strength; COST is base-building; BAC is a stealth accumulator; BKNG offers sector exposure; REGN provides stability. ?? Execution: Action: set alerts on breakout + ladder entries on confirmation. ?? ???? #RiskManaged #TopPicks ???? ?? Source: https://stocktwits.com/KimberlyCameron4907/message/632828877

0 · Reply

signalg0o0vq Oct. 18 at 4:18 AM

$PFE $MRNA $BNTX $JNJ 💉 Biotech giants waking from hibernation — $PFE showing early signs of rotation, $MRNA loading volume like it’s prepping for a moon mission 🚀 $BNTX and $JNJ both building tight patterns that scream accumulation. Sentiment’s been dead quiet, and that’s exactly how these runs begin — stealth, silence, then fireworks 💥 https://stocktwits.com/BrianWatson9291/message/632825018

1 · Reply

Wenwenwenwenwenwen Oct. 18 at 3:56 AM

$JNJ before any pull back imo this will touch $200 before it attempts a pull back….

0 · Reply

Suite510 Oct. 18 at 3:10 AM

$KVUE $JNJ MDL Judge Allows Talc Plaintiffs to Sue Additional Johnson & Johnson Affiliates: ‘This Is a Significant Ruling’ On Tuesday, U.S. District Judge Michael Shipp of the District of New Jersey ruled that the plaintiffs’ steering committee in the talc multidistrict litigation could add Kenvue, Holdco and Janssen as defendants in their master complaint.

0 · Reply

SuperGreenToday Oct. 18 at 12:59 AM

$JNJ Share Price: $193.24 Contract Selected: Nov 14, 2025 $195 Calls Buy Zone: $2.41 – $2.98 Target Zone: $4.05 – $4.95 Potential Upside: 58% ROI Time to Expiration: 27 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

harry333 Oct. 18 at 12:02 AM

$JNJ https://finance.yahoo.com/news/jury-orders-johnson-johnson-jnj-201942354.html

0 · Reply

MoneyGroupLLC Oct. 17 at 9:00 PM

Enter: $JNJ NOV 07 2025 $195 CALLS Buy in Price: $2.40 - $2.61 Take Profit: $5.35 Stop Bleeding: $2.11 ROI Potential: 123% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

Quantumup Oct. 17 at 7:30 PM

Citi⬆️ $PTGX's PT to $96 from $72 and kept it at a Buy rating after updating its model and said Rusfertide's De-Risked Profile Supports Upside $JNJ $TAK $BMY $ABVX Citi additionally said:

0 · Reply

TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care

Oct 15, 2025, 7:03 PM EDT - 2 days ago

J&J faces first UK lawsuits alleging its baby powder caused cancer

Oct 15, 2025, 2:04 PM EDT - 2 days ago

These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings

Oct 15, 2025, 1:56 PM EDT - 2 days ago

Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst

Oct 15, 2025, 7:51 AM EDT - 2 days ago

Johnson & Johnson reveals 2025 sales forecast and plans for its orthopedics business

Oct 14, 2025, 7:30 PM EDT - 3 days ago

'NEVER BEEN STRONGER': Johnson & Johnson leader touts latest innovations

Oct 14, 2025, 12:36 PM EDT - 3 days ago

Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript

Oct 14, 2025, 10:01 AM EDT - 3 days ago

Citi (C) Posts Strong Earnings, Stuffed Crust Strengthens DPZ, JNJ Slides

C DPZ

Oct 14, 2025, 8:58 AM EDT - 3 days ago

Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again

Oct 14, 2025, 8:56 AM EDT - 3 days ago

Johnson & Johnson to spin off orthopedics unit after raising 2025 sales forecast

Oct 14, 2025, 8:51 AM EDT - 3 days ago

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook

Oct 14, 2025, 7:44 AM EDT - 3 days ago

Johnson & Johnson's stock heads for a record after a profit beat and plans for another spinoff

Oct 14, 2025, 7:33 AM EDT - 3 days ago

J&J CEO Joaquin Duato on Q3 results: We are entering an era of accelerated growth

Oct 14, 2025, 6:32 AM EDT - 3 days ago

J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains

Oct 14, 2025, 6:30 AM EDT - 3 days ago

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025

Oct 14, 2025, 6:26 AM EDT - 3 days ago

J&J to spin off orthopedics business, raises full-year forecast

Oct 14, 2025, 6:21 AM EDT - 3 days ago

Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business

Oct 14, 2025, 6:20 AM EDT - 3 days ago

Johnson & Johnson said Tuesday it plans to separate its artificial hip and knee business into a stand-alone company to be called DePuy Synthes

Oct 14, 2025, 6:20 AM EDT - 3 days ago

Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook

Oct 13, 2025, 12:27 PM EDT - 4 days ago

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch

Oct 12, 2025, 9:00 AM EDT - 5 days ago

Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make

PTGX

Oct 10, 2025, 6:36 PM EDT - 7 days ago

US FDA adds boxed warning to J&J, Legend Biotech's cancer therapy

LEGN

Oct 10, 2025, 4:20 PM EDT - 7 days ago

Johnson & Johnson recommends shareholders reject “mini-tender” offer by Tutanota

Oct 10, 2025, 1:21 PM EDT - 7 days ago

RTW Investments' Rod Wong: Expect more deals in biotech space

PTGX XBI

Oct 10, 2025, 1:06 PM EDT - 7 days ago

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report

PTGX

Oct 10, 2025, 11:25 AM EDT - 7 days ago

Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports

PTGX

Oct 10, 2025, 11:13 AM EDT - 7 days ago

Johnson & Johnson in Talks to Buy Protagonist Therapeutics

PTGX

Oct 10, 2025, 7:48 AM EDT - 7 days ago

Johnson & Johnson: A Safe Haven That's Quietly Becoming A Bit Overpriced

Oct 10, 2025, 7:30 AM EDT - 7 days ago

Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress

Oct 10, 2025, 2:42 AM EDT - 8 days ago

Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Oct 9, 2025, 4:24 PM EDT - 8 days ago

Johnson & Johnson to Participate in the UBS Global Healthcare Conference

Oct 8, 2025, 2:42 AM EDT - 10 days ago

Johnson & Johnson ordered to pay $966 million in talc cancer case after jury finds company liable

Oct 7, 2025, 4:19 PM EDT - 10 days ago

LA County Jury Hits Johnson & Johnson with Nearly $1 Billion Verdict

Oct 7, 2025, 10:50 AM EDT - 10 days ago

Johnson & Johnson ordered to pay $966 million after jury finds company liable in talc cancer case

Oct 7, 2025, 8:05 AM EDT - 10 days ago

TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis

Oct 7, 2025, 8:05 AM EDT - 10 days ago

Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill

Oct 7, 2025, 8:00 AM EDT - 10 days ago

Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses

Oct 6, 2025, 4:00 PM EDT - 11 days ago

Johnson & Johnson to Participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Oct 6, 2025, 1:29 PM EDT - 11 days ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

Oct 4, 2025, 12:18 PM EDT - 13 days ago

October Dogs Of The Dow Flash One Ideal 'Safer' Dividend Buy

AMGN AMZN BA CRM CSCO CVX DIS

Oct 3, 2025, 4:00 PM EDT - 14 days ago

Examining JNJ Breakout: Bull Flag & Options Show Upside Potential

Sep 30, 2025, 9:45 AM EDT - 17 days ago

Why JNJ Stock Defines Shareholder Supremacy In Healthcare

Sep 29, 2025, 8:00 AM EDT - 18 days ago

U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

Sep 28, 2025, 1:00 AM EDT - 20 days ago

Best Dividend Aristocrats For October 2025

ABT ADP ATO BDX BEN CAH CHRW

Sep 26, 2025, 10:18 PM EDT - 21 days ago

'I'm an optimist,' says Johnson & Johnson CEO on its R&D investment

Sep 26, 2025, 8:43 PM EDT - 21 days ago

Watch Jim Cramer's interview with Johnson & Johnson CEO Joaquin Duato

Sep 24, 2025, 5:17 PM EDT - 23 days ago

Johnson & Johnson (JNJ) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 23, 2025, 5:52 AM EDT - 24 days ago

J&J to withdraw acid reflux device from non-US markets, Bloomberg News reports

Sep 22, 2025, 3:37 PM EDT - 25 days ago

These are the top 22 stocks pushing the S&P 500 into record territory — and it's not all Big Tech

AAPL ABBV AMZN AVGO COST GOOG GOOGL

Sep 19, 2025, 5:28 PM EDT - 4 weeks ago

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

LiquidThetaLEAPS Oct. 18 at 6:40 AM

0 · Reply

dDxsm8 Oct. 18 at 5:43 AM

0 · Reply

investblwiit Oct. 18 at 5:13 AM

0 · Reply

signalg0o0vq Oct. 18 at 4:18 AM

1 · Reply

Wenwenwenwenwenwen Oct. 18 at 3:56 AM

$JNJ before any pull back imo this will touch $200 before it attempts a pull back….

0 · Reply

Suite510 Oct. 18 at 3:10 AM

0 · Reply

SuperGreenToday Oct. 18 at 12:59 AM

0 · Reply

harry333 Oct. 18 at 12:02 AM

$JNJ https://finance.yahoo.com/news/jury-orders-johnson-johnson-jnj-201942354.html

0 · Reply

MoneyGroupLLC Oct. 17 at 9:00 PM

Enter: $JNJ NOV 07 2025 $195 CALLS Buy in Price: $2.40 - $2.61 Take Profit: $5.35 Stop Bleeding: $2.11 ROI Potential: 123% Exit Within: 3 Weeks https://moneygroup.us/alerts

0 · Reply

Quantumup Oct. 17 at 7:30 PM

Citi⬆️ $PTGX's PT to $96 from $72 and kept it at a Buy rating after updating its model and said Rusfertide's De-Risked Profile Supports Upside $JNJ $TAK $BMY $ABVX Citi additionally said:

0 · Reply

dudebob Oct. 17 at 7:23 PM

~50,000 $KODK for the pharma precursors play. Long & strong 💪 Thoughts $DJT $AVTR $JNJ $TEVA ? Is this a foolish move, or a decent long term play?

0 · Reply

harry333 Oct. 17 at 6:50 PM

$JNJ

1 · Reply

ProfitGainer Oct. 17 at 6:47 PM

$ABVC ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments $MRNA $JNJ

0 · Reply

ZacksResearch Oct. 17 at 6:34 PM

$JNJ just proved it’s still a powerhouse. 💪 Strong Q3 results, an upbeat sales outlook, and a growing drug pipeline show serious resilience — even with the Stelara LOE on deck. Full post-earnings breakdown here 👉 https://www.zacks.com/stock/news/2771349/should-you-buy-sell-or-hold-jj-stock-after-robust-q3-earnings?cid=sm-stocktwits-2-2771349-teaser-16711&ADID=SYND_STOCKTWITS_TWEET_2_2771349_TEASER_16711

0 · Reply

harry333 Oct. 17 at 5:57 PM

$JNJ

1 · Reply

ZacksResearch Oct. 17 at 5:34 PM

$JNJ posts strong Q3 results — what's next for this pharma giant? 💊 Revenues climbed 6.8% to $24B, with adjusted EPS up around 16% YoY. Key drugs and MedTech growth fueled this performance, driving a raised sales guidance for 2025. 📈 Full breakdown here 👉 https://www.zacks.com/stock/news/2771349/should-you-buy-sell-or-hold-jj-stock-after-robust-q3-earnings?cid=sm-stocktwits-2-2771349-body-16701&ADID=SYND_STOCKTWITS_TWEET_2_2771349_BODY_16701

0 · Reply

harry333 Oct. 17 at 5:32 PM

$JNJ

0 · Reply

harry333 Oct. 17 at 5:18 PM

$JNJ

0 · Reply

1ightningAlerts Oct. 17 at 5:16 PM

1ightning® Options Trade Alert (Actionable) | Buy $JNJ Oct 31 $195 Call | Enter: $2.10 Exit: $3.26 | Profit: 55.15% ROI | https://1ightning.com/scalps

1 · Reply

harry333 Oct. 17 at 3:43 PM

$JNJ whats going on with this shitm never comes down. Will it even break 190 below!...

0 · Reply

JoeCoolTrader Oct. 17 at 3:29 PM

The talc story is old news. Limited financial hit. The only unknown is the number of ambulance chasers. $JNJ $KVUE $SPY

0 · Reply

Suite510 Oct. 17 at 3:27 PM

$KVUE $JNJ 3 month chart looks like poo 💩 still in decline mode PT12 more talc on way soon lol 😂

0 · Reply

Market Cap	462.69B
Revenue (ttm)	88.82B
Net Income (ttm)	14.07B
EPS (ttm)	N/A
PE Ratio	18.42
Forward PE	17.60
Profit Margin	15.84%
Debt to Equity Ratio	0.50

Volume	7,764,400
Avg Vol	8,485,024
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	90%
Beta	0.40
Analysts	Strong Sell
Price Target	$199.17